Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

FBDIX vs. BIB: which is better?

Bottom line

FBDIX vs BIB: the short answer

FBDIX (Franklin Biotechnology Discovery Fund) and BIB (ProShares Ultra Nasdaq Biotechnology) are quite different portfolios: only about 32% of their top holdings (by weight) are shared.

But BIB is far broader, holding 267 positions to 126 for FBDIX, so beyond the top names it adds exposure FBDIX doesn't have.

BIB is cheaper at 0.95% vs 1.01% — a difference of $6.00 a year per $10,000 invested.

Over five years, FBDIX returned +5.0% a year vs −1.0% for BIB.

FBDIX has a front-end sales load of up to 5.5%; the other does not.

Updated Nov 19, 2026

FBDIX vs BIB side by side

FBDIXBIB
TypeMutual fundETF
Fund familyFranklin TempletonProShares
CategoryTechnology SectorTechnology Sector
Expense ratio1.01%0.95%
Annual cost per $10k$101$95
10-yr cost on $10k (prospectus)$1,728$1,401
Max front load5.5%None
12b-1 fee0.25%—
1-yr return+43.9%+59.3%
5-yr return (annualized)+5.0%−1.0%
10-yr return (annualized)+6.4%+1.4%
Best quarter+29.5%+56.2%
Worst quarter−24.5%−42.7%
Net assets (fund)$1.2B$73.7M
Number of holdings126267
Portfolio turnover38%29%
Returns as ofDec 31, 2025Dec 31, 2025

Source: SEC Form N-PORT and fund prospectuses

Year-by-year returns

YearFBDIXBIBDifference
2025+52.3%+59.3%−7.0%
2024+4.0%−10.0%+14.0%
2023+18.4%−1.3%+19.7%
2022−12.7%−28.6%+16.0%
2021−17.7%−5.9%−11.8%
2020+29.9%+39.7%−9.8%
2019+34.8%+45.5%−10.7%
2018−15.7%−24.4%+8.7%
2017+18.8%+40.8%−22.0%
2016−17.2%−44.2%+27.1%

Source: Fund prospectus bar charts

Holdings overlap

8 of FBDIX's top 25 holdings also appear in BIB's top 25.

Shared top holdings
HoldingFBDIXBIB
Amgen, Inc.4.39%4.48%
Gilead Sciences, Inc.3.86%4.66%
Regeneron Pharmaceuticals, Inc.3.77%3.21%
Argenx SE3.62%1.19%
Vertex Pharmaceuticals, Inc.3.54%4.65%
Revolution Medicines, Inc.3.01%1.57%
Guardant Health, Inc.2.76%0.85%
Insmed, Inc.1.99%1.16%

Source: SEC Form N-PORT

FBDIX top 10

  1. Jazz Pharmaceuticals plc — 5.66%
  2. Amgen, Inc. — 4.39%
  3. Gilead Sciences, Inc. — 3.86%
  4. Regeneron Pharmaceuticals, Inc. — 3.77%
  5. Argenx SE — 3.62%
  6. Vertex Pharmaceuticals, Inc. — 3.54%
  7. Franklin Institutional U.S. Government Money Market Fund — 3.18%
  8. Revolution Medicines, Inc. — 3.01%
  9. Guardant Health, Inc. — 2.76%
  10. Ascendis Pharma A/S — 2.56%

BIB top 10

  1. N/a — 7.35%
  2. ProShares GENIUS Money Market ETF — 6.80%
  3. Gilead Sciences, Inc. — 4.66%
  4. Vertex Pharmaceuticals, Inc. — 4.65%
  5. Amgen, Inc. — 4.48%
  6. N/a — 3.94%
  7. N/a — 3.26%
  8. Regeneron Pharmaceuticals, Inc. — 3.21%
  9. N/a — 2.62%
  10. Alnylam Pharmaceuticals, Inc. — 2.01%

FAQ

What is the difference between FBDIX and BIB?
FBDIX (Franklin Biotechnology Discovery Fund) and BIB (ProShares Ultra Nasdaq Biotechnology) are quite different portfolios: only about 32% of their top holdings (by weight) are shared. But BIB is far broader, holding 267 positions to 126 for FBDIX, so beyond the top names it adds exposure FBDIX doesn't have.
Which is cheaper, FBDIX or BIB?
BIB has the lower expense ratio (0.95%).
Should I own both FBDIX and BIB?
Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.

Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.